Publications and news

Selected publications

  • Understanding clinical development of Chimeric Antigen Receptor T cell therapies. de Wilde S, Guchelaar HJ, Zandvliet ML, Meij P.  Cytotherapy. 2017; 19(6):703-709
  • Clinical development of gene- and cell-based therapies: overview of the European landscape. de Wilde S, Guchelaar HJ, Zandvliet ML, Meij P. Mol Ther Methods Clin Dev. 2016 30; 3:16073. 
  • Development of cell therapy medicinal products by academic institutes. de Wilde S, Guchelaar HJ, Herberts C, Lowdell M, Hildebrandt M, Zandvliet M, Meij P. Drug Discov Today. 2016; 21(8):1206-12. 
  • Hurdles in clinical implementation of academic advanced therapy medicinal products: A national evaluation. de Wilde S, Veltrop-Duits L, Hoozemans-Strik M, Ras T, Blom-Veenman J, Guchelaar HJ, Zandvliet M, Meij P. Cytotherapy. 2016; 18(6):797-805.
  • Effective treatment of refractory CMV reactivation after allogeneic stem cell transplantation with in vitro generated CMV pp65-specific CD8+ T-cell lines. Meij P, Jedema I, Zandvliet ML, van der Heiden PLJ, van Egmond HME, van Liempt PAG, Hoogstraten C, van de Meent M, Veld SAJ, Marijt WA, von dem Borne PA, Lankester AC, Halkes CJM, Falkenburg JHF. J of Immunother.  2012; 35(8):621-8.
  • Generation and administration of HA-1 specific T-cell lines for the treatment of patients with relapsed leukemia after allogeneic stem cell transplantation: a pilot study. Meij P, Jedema I, van der Hoorn MAWG, Bongaerts R, Cox L, Wafelman AR, Marijt WA, Willemze R, Falkenburg JHF. Haematologica 2012; 97(8):1205-8.

News